Tower Research Capital LLC TRC boosted its position in Repare Therapeutics Inc. (NASDAQ:RPTX – Free Report) by 533.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,316 shares of the company’s stock after buying an additional 9,529 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Repare Therapeutics were worth $111,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of RPTX. Deutsche Bank AG bought a new stake in Repare Therapeutics in the fourth quarter valued at about $40,000. UBS Group AG boosted its stake in Repare Therapeutics by 26.3% in the third quarter. UBS Group AG now owns 3,551 shares of the company’s stock valued at $43,000 after acquiring an additional 739 shares during the period. Wells Fargo & Company MN boosted its stake in Repare Therapeutics by 185.8% in the fourth quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock valued at $45,000 after acquiring an additional 1,977 shares during the period. Lazard Asset Management LLC acquired a new position in Repare Therapeutics in the fourth quarter valued at approximately $114,000. Finally, Compagnie Lombard Odier SCmA acquired a new position in Repare Therapeutics in the first quarter valued at approximately $140,000. 85.09% of the stock is owned by institutional investors.
Repare Therapeutics Trading Down 1.0 %
Shares of NASDAQ RPTX opened at $9.66 on Friday. The stock has a 50 day simple moving average of $10.07 and a 200-day simple moving average of $10.20. The company has a market cap of $406.59 million, a PE ratio of -64.40 and a beta of 0.05. Repare Therapeutics Inc. has a 12-month low of $8.02 and a 12-month high of $18.68.
Analyst Ratings Changes
Repare Therapeutics Profile
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
- Five stocks we like better than Repare Therapeutics
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- MarketBeat Week in Review – 8/28 – 9/1
- How to Choose Top Rated Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- The How and Why of Investing in Gold Stocks
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.